• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Harpoon Therapeutics appoints Hans-Peter Gerbe chief scientific officer

Harpoon Therapeutics appoints Hans-Peter Gerbe chief scientific officer

November 11, 2016
CenterWatch Staff

Harpoon Therapeutics appointed Dr. Hans-Peter Gerber chief scientific officer. Harpoon is a preclinical stage biotechnology company founded by MPM Capital that is developing two novel classes of T-cell recruiting therapies for treating cancer patients.

With more than 20 years of oncology drug development experience, Dr. Gerber is a world-renowned expert in developing antibody-based therapies that redirect the immune system to eliminate cancer cells. He has deep expertise in target identification and validation, selection of therapeutic modalities and lead compounds, the development of companion diagnostics, translational medicine, and early clinical development and regulatory filings.

“We are extremely pleased to have Hans-Peter join Harpoon’s leadership team,” said Patrick A. Baeuerle, Harpoon’s CEO and MPM Capital managing director. “The breadth of his experience will support Harpoon’s strategy to develop innovative cancer therapies that use T-cell recruiting antibodies against hematologic and solid tumor targets. With his scientific guidance and successful track record for executing external collaborations and licensing deals with academia and corporate partners, we expect to expand Harpoon’s pipeline of breakthrough cancer therapies.”

Dr. Gerber joins Harpoon from Pfizer where he was most recently vice president and chief scientific officer of Bioconjugates Discovery and Development at its Oncology Research Unit. Prior to this role, he held positions at Wyeth Discovery Research—subsequently acquired by Pfizer—and at Seattle Genetics, where he was head of the Translational Biology Department and contributed to the development of therapeutic antibodies and antibody drug conjugates (ADCs). Earlier in his career, he spent 11 years at Genentech in research studying the mechanisms involved in regulating blood vessel formation and developing therapeutic antibodies interfering with tumor growth.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing